Evaluation of dupilumab and benralizumab on peripheral airway resistance and reactance.

This article discusses the impact of biologic therapies on small airway dysfunction (SAD) in patients with severe asthma. The study analyzed the effects of two biologic drugs, benralizumab and dupilumab, on peripheral airway resistance and reactance using airway oscillometry (AO). The results showed that dupilumab was more effective than benralizumab in improving peripheral airway resistance and compliance. The findings suggest that dupilumab, which blocks IL-13 signaling, may be a better treatment option for severe asthma patients with SAD. However, further research is needed to confirm these findings. [Extracted from the article]